Hot Flashes and Your Heart: What the Newest Hormone Therapy Data Finally Gets Right
I’ve had the same conversation more times than I can count. A woman in her 50s sits across from me, miserable: hot flashes every two hours, no sleep, joint pain, mood swings that have her convinced something is seriously wrong. She needs hormone therapy. She wants hormone therapy. And then she says it: “But isn’t it bad for my heart?” That fear around hormone therapy heart risk has a specific origin, and it has cost women decades of unnecessary suffering.
The fear came directly from the 2002 Women’s Health Initiative study, which alarmed an entire generation of doctors and patients overnight. The WHI reported elevated heart risks, and physicians stopped prescribing hormones almost immediately. Nobody told women that the study used older subjects, started them on hormones years after menopause, and used synthetic oral conjugated equine estrogens with medroxyprogesterone acetate. Nobody connected those dots between the study design and the frightening headlines that followed.
Now, a new secondary analysis published in JAMA Internal Medicine in November 2025 has revisited that data with sharper questions. It looked specifically at women who had hot flashes and asked: for these women, what does hormone therapy actually do to heart risk? The findings are worth understanding in detail, because they change how I counsel every woman who walks through my door scared about her cardiovascular health.
What This Study Found About Hormone Therapy Heart Risk
The researchers analyzed data from 27,347 postmenopausal women enrolled in the original WHI trials. They tracked whether women had moderate to severe hot flashes at enrollment, then followed their cardiovascular outcomes based on when and how they received hormone therapy.
In women aged 50 to 59 with hot flashes, hormone therapy had no measurable effect on cardiovascular risk. The hazard ratios were 0.85 for estrogen alone and 0.84 for estrogen plus progestin. Practically speaking, those numbers mean neutral. No harm. Not even a statistical trend toward harm.
In women aged 60 to 69 with hot flashes, the data showed no definitive signal of harm either. That is an important nuance. It is not a green light, but it is not a red one.
The picture changed significantly for women aged 70 and older. In that group, cardiovascular risk increased substantially: a hazard ratio of 1.95 for estrogen alone and 3.22 for estrogen plus progestin. Those are real numbers. That is not a borderline finding, and I’m not going to soften it.
What Hazard Ratios Mean in Real Life
When a study reports a hazard ratio, it compares event rates between groups. A hazard ratio of 0.85 in the 50 to 59 age group means women on hormone therapy trended slightly better than those on placebo. A hazard ratio of 3.22 in women over 70 means three times the rate of cardiovascular events.
Translation: the actual story here is not “HRT is bad for your heart.” The real story is “starting synthetic oral HRT at 70, in the presence of hot flashes, carries serious cardiovascular risk.” These are very different claims. Medicine has been treating them as the same claim for two decades.
Why Timing Changes Everything
This study confirms what researchers call the “timing hypothesis.” Estrogen protects cardiovascular tissue when started during the early years of menopause, while arteries are still relatively healthy and responsive to estrogen’s anti-inflammatory, vessel-relaxing effects. Estrogen can protect the cardiovascular system before arterial plaque has established itself.
Start it years later, when arterial changes have already progressed, and you are introducing a hormone into a vascular environment that no longer responds the same way. The protective benefit is gone. In older women on synthetic formulations, you may introduce real risk instead.
So when women in their late 60s come to me having never been offered a hormone conversation in their 50s, I’m not just frustrated on their behalf. I’m looking at a decade of missed opportunity to support their cardiovascular health. Their doctors were following the 2002 guidelines, not the emerging evidence that those guidelines were population-specific and formulation-specific.
The Synthetic Hormone Problem
This study used conjugated equine estrogens and medroxyprogesterone acetate. Those are synthetic hormones. They are not bioidentical estradiol or micronized progesterone. The formulation matters more than most doctors acknowledge.
Most of the negative cardiovascular findings in older hormone research used these synthetic preparations, particularly in oral form. Oral estrogen passes through the liver and triggers clotting factor production in a way that transdermal delivery does not. The WHI was not designed to test transdermal bioidentical hormones. None of the 27,347 women in this new analysis used them. When you draw conclusions from this data, that matters.
What This Means for You
If you are in your 50s and having moderate to severe hot flashes, the evidence strongly supports discussing hormone therapy with your provider. This study of nearly 27,000 women found no significant cardiovascular downside in your age group. Treating your symptoms is not reckless. Avoiding treatment out of fear of a 2002 study that did not study women like you is no longer acceptable as standard care in my practice.
In your 60s, the picture is more nuanced and requires individual assessment: your cardiovascular health baseline, your symptom severity, and your formulation options. This is not a reason to avoid the conversation. It is a reason to have it with someone who actually understands the full picture.
Women aged 70 or older having hot flashes face a different situation. This data says initiating hormone therapy at that point, especially with oral synthetic formulations, carries real cardiovascular risk. That does not close every door. But it does shift the calculus, and I would not be doing you any favors by pretending otherwise.
The larger point: women deserve individualized, evidence-based care. That means a provider who reads the actual data, not the 2002 headlines.
Key Takeaways
- In 27,347 women from the WHI trials, hormone therapy showed no significant heart risk for women aged 50 to 59 with hot flashes.
- Women aged 60 to 69 with hot flashes showed no clear cardiovascular harm, though individual assessment is warranted.
- Women aged 70 and older with hot flashes had significantly elevated cardiovascular risk: hazard ratios of 1.95 to 3.22 depending on formulation.
- This study used synthetic oral formulations; bioidentical transdermal options carry a different risk profile not captured here.
- Starting hormone therapy during the early menopause years, when symptoms are active, provides the most cardiovascular benefit and the least risk.
Frequently Asked Questions
Does hormone therapy cause heart attacks? It depends entirely on when you start, what you take, and how you take it. In women aged 50 to 59 with active hot flashes, a new JAMA analysis of 27,347 women found no significant cardiovascular harm from hormone therapy. In women aged 70 and older, that same data showed substantially elevated risk. The blanket fear of hormone therapy and heart attacks does not hold up against a careful reading of the evidence.
What does the WHI study actually show about HRT and the heart? The original WHI study used older women, many of them well past their first decade of menopause, on oral synthetic estrogen and synthetic progestins. When researchers went back and looked specifically at women with hot flashes who started therapy closer to menopause onset, the cardiovascular picture changed. The 2002 harm headline applied to a specific population on a specific formulation. It was never the whole story.
Understanding the Timing Window for Hormone Therapy
What is the “window of opportunity” for starting hormone therapy? Estrogen provides the most cardiovascular benefit when started within the first 10 years of menopause, while arteries are still responsive. Starting hormone therapy after age 60, particularly in women who have been estrogen-depleted for years, does not yield the same benefits and may introduce risk instead. This is why I encourage women to have the hormone therapy conversation in their late 40s and early 50s, not after they’ve endured a decade of symptoms.
Should I stop hormone therapy when I reach a certain age? There is no universal cutoff age. The decision to continue hormone therapy should come from ongoing individual assessment: your current health status, symptom burden, risk factors, and formulation. The 2025 JAMA data supports caution when initiating therapy in women over 70. Women who started therapy in their early 50s and are doing well are in a different situation than women initiating it for the first time at 72.
Bioidentical vs. Synthetic Hormones and Heart Risk
Does bioidentical hormone therapy have the same heart risk as synthetic HRT? This study looked specifically at conjugated equine estrogens and medroxyprogesterone acetate, both synthetic. Bioidentical estradiol, particularly in transdermal form, bypasses the liver, creates fewer clotting factors, and has a different metabolic profile. Most cardiovascular risk findings in older HRT research tie directly to oral synthetic formulations. Transdermal bioidentical options deserve their own conversation with a clinician familiar with the current evidence.
Is it ever too late to start hormone therapy for symptom relief? For women over 70 with active hot flashes, this 2025 data shows initiating hormone therapy carries real cardiovascular risk, especially with oral synthetic formulations. This is not a blanket prohibition for every woman in every circumstance. A thorough evaluation of individual risk, symptom severity, and available formulations should drive the decision. The data is a reason for serious caution, not a conversation-ender.
Dr. Betty’s Bottom Line
This 2025 JAMA analysis finally does something I’ve been waiting for: it stops treating all women on all hormone therapies as one group and starts asking real clinical questions. If you have hot flashes and you’re in your 50s, the data says your cardiovascular risk from hormone therapy is not meaningful. The fear that kept women suffering through symptoms for over two decades is not supported by a careful reading of 27,347 women’s worth of data.
What I see in my practice is women who never received this information. They were told “no hormones” by doctors acting on a 2002 headline. Women in their 60s come to me having endured 15 years of symptoms they did not have to endure. That is a failure of care, not caution.
If you’re in your 50s and having hot flashes, you are not wrong to want relief, and you are not being reckless to ask for it. You deserve a provider who looks at your specific picture, discusses bioidentical transdermal options the WHI never tested, and makes a recommendation based on the full body of evidence. That is exactly what we do.
In-person care at Living Well Dallas is available for patients in the Dallas area. Menrva Health offers personalized hormone evaluation and management through telehealth in all 50 states.
Source: Rossouw JE, Aragaki AK, Manson JE, et al. Menopausal Hormone Therapy and Cardiovascular Diseases in Women With Vasomotor Symptoms: A Secondary Analysis of the Women’s Health Initiative Randomized Clinical Trials. JAMA Intern Med. 2025;185(11):1330-1339. doi:10.1001/jamainternmed.2025.4510